Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Biphase Extended Release Tablet Formulation for Nerve Agent Pretreatment

    SBC: Zymeron Corporation            Topic: CBD181004

    Given the unforeseen/unanticipated use of nerve agents in the battlefield and on the homeland, military personnel can benefit from this oncedaily pretreatment. It may also be desirable to pretreat certain medical and emergency aid personnel following a known/suspected nerveagent attack. Also, a novel, improved PB extended release formulations can be commercialized for the treatment of myasthenia g ...

    SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
  2. Rapid Point-of-Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood

    SBC: Zymeron Corporation            Topic: NIAID

    TuberculosisTBis currently the leading infectious cause of death worldwideTB treatment includes multiple different combinations of antibioticsdosesand long time periodsThe current standard includes an intensive phase ofmonthsfollowed by a continuation phase of eitherormonthsHowevertreatment outcome can be poor due to drug drug interactionsimpaired medication adherencedrug absorption and metabolism ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine

    SBC: ADJUVANCE TECHNOLOGIES, INC.            Topic: NIAID

    Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenicrequiring use of an immunological adjuvant for best effectAdjuvance s semi synthetic saponin adjuvant TiterQuilTQLhas shown remarkable efficacy with a variety of antigens with no detectable reactogenicityWhen combined withof the leading vaccines against influenzaFluzoneFluarix and Flublokstriking aug ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Targeted Degradation of HIV Gag Polyprotein by Gag-PROTAC Reagents

    SBC: Zymeron Corporation            Topic: NIAID

    HIV disease continues to be a serious health issue for the whole worldCurrentlyantiretroviral therapyARTis a widely accepted treatment to HIV infected patientswhich reduces morbidity and mortality and the potential for HIV transmission by suppressing viral replicationHowevertreatment outcomes of ART are limited due to the high adherence requirement and occurrence of drug resistanceProteolysis targ ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Liposomal Platform for Spontageous, Particleized Presentation of HIV Trimer Immunogens

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Over one million Americans andmillion people worldwide are infected with HIVmaking it one of the most pressing public health concerns of our timeUnfortunatelythere are no vaccines available and treatment requires lifelong anti retroviral therapiesThis proposal combines two technologies for the development of a vaccine against HIVEnva novel adjuvantspontaneous nanoliposome antigen particleizationSN ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: Zymeron Corporation            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. SBIR PHASE 1- TOPIC 394- COMBINATORY TREATMENT MODALITIES UTILIZING RADIATION TO LOCALLY ACTIVATE OR RELEASE SYSTEMICALLY DELIVERED THERAPEUTICS.

    SBC: Zymeron Corporation            Topic: NCI

    Photodynamic therapyPDTutilizes light beam to activate photosensitizers to produce cytotoxic reactive oxygen speciesROSand it has been proposed as a potent treatment to combine with Radiation TherapyRTespecially for the idea of using X ray beam to locally activate PDTXPDTMajority studies about XPDT have used nanoscintillators as the X ray transducer to activate photosensitizersHoweverthe materials ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 382- INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW

    SBC: Cell Microsystems, Inc.            Topic: NCI

    Combining both genomic analysis and highEresolution imaging on a cellEbyEcell basis typically relies on customized technology which often requires significant expertise and capital costCell MicrosystemsInchas partnered with Peter SimsPhD of Columbia University to commercialize a novel workflow for integrated imaging and sample preparation for single cell transcriptomic analysisDrSims workflowSingl ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 356: FLUOROGENIC ASSAY PLATFORM FOR CIRCULAR RNA DETECTION

    SBC: Lucerna Inc.            Topic: NCI

    Circular RNAscircRNAsare a novel class of modified RNAs that are an abundant component of the epitranscriptomePutative functions of circRNAsinclude miRNA sequestrationRNA binding protein scaffoldingmRNA trappingand protein translation regulationDeregulation in one or more of these roles has been linked to several types of cancerOne well studied circRNAciRSis believed to act as a miRNAsponge and in ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. An integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings.

    SBC: CERTIRX CORPORATION            Topic: NIDA

    Under the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop an integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government